Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) — Working Capital to Net Assets Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has a Working Capital to Net Assets ratio of 45.4% as of March 2026. Working capital of CN¥3.51 Billion (current assets of CN¥4.34 Billion minus current liabilities of CN¥826.26 Million) is measured against net assets of CN¥7.74 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shanghai Allist Pharmaceuticals Co. Ltd. (688578) liquidity interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanghai Allist Pharmaceuticals Co. Ltd. A Working Capital to Net Assets (2017–2025)
This chart shows how Shanghai Allist Pharmaceuticals Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the ratio stands at 45.4%, reflecting working capital of CN¥3.51 Billion against net assets of CN¥7.74 Billion CNY. For the complete balance sheet picture, see 688578 total assets.
Annual Working Capital to Net Assets for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 688578 financial resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 23.4% | CN¥3.36 Billion | CN¥14.40 Billion | CN¥4.17 Billion | CN¥805.62 Million | ▼ -44.4 pp |
| 2024 | 67.8% | CN¥3.58 Billion | CN¥5.28 Billion | CN¥4.18 Billion | CN¥600.60 Million | ▲ +4.5 pp |
| 2023 | 63.2% | CN¥2.52 Billion | CN¥3.98 Billion | CN¥2.91 Billion | CN¥390.03 Million | ▼ -0.5 pp |
| 2022 | 63.7% | CN¥2.03 Billion | CN¥3.19 Billion | CN¥2.29 Billion | CN¥254.62 Million | ▼ -10.9 pp |
| 2021 | 74.6% | CN¥2.22 Billion | CN¥2.97 Billion | CN¥2.37 Billion | CN¥156.12 Million | ▼ -14.7 pp |
| 2020 | 89.3% | CN¥2.57 Billion | CN¥2.88 Billion | CN¥2.68 Billion | CN¥109.01 Million | ▲ +18.2 pp |
| 2019 | 71.1% | CN¥842.17 Million | CN¥1.18 Billion | CN¥985.84 Million | CN¥143.66 Million | ▲ +185.4 pp |
| 2018 | -114.3% | CN¥-81.17 Million | CN¥71.04 Million | CN¥222.09 Million | CN¥303.26 Million | ▼ -187.0 pp |
| 2017 | 72.7% | CN¥277.29 Million | CN¥381.26 Million | CN¥404.67 Million | CN¥127.37 Million | — |